상단 바로가기
본문 바로가기
하단 바로가기
Overview
Program Schedule
Keynote Speakers
Registration form
Location
KOR
ENG
전체메뉴
Overview
Program Schedule
Keynote Speakers
Registration form
Location
본문
서브비주얼
Registration form
Please fill in the blank
Name
*
Organization
*
Title/Position
*
Email
*
- Pre-registered questions will be selected and answered at the event
Question 1
Choose the topic
Session 1 (Virtual) : Building a novel pandemic preparedness program
Session 2 : Development of therapeutic human monoclonal antibodies against SFTSV infection
Session 3 : Bacteriophages and Endolysins Combating Multidrug Resistant (MDR) Pathogens
Session 4 : NIH-Supported Clinical Trial of Phage Therapy for Cystic Fibrosis Begins
Session 5 : Research status of TLR5’s immune adjuvant
Session 6 : accine adjuvants research
Session 7 : The future of pandemic preparedness: Building collaborations and EV-D68 as a test case for NIAID/VRC's PREMISE program
(AM)Session 1 (Virtual) : One Health approach to antimicrobial resistance
(AM)Session 2 (Virtual) : One Health Antimicrobial Resistance research landscape in Singapore
(AM)Session 3 (Virtual) : Population CPE evolution in Singapore
(AM)Session 4 (Virtual) : Long Covid-19
(AM)Session 5 (Virtual) : Long COVID treatment trials: pathogenesis guides intervention
(PM)Session 1 (Virtual) : A research about national seroepidemiology and immunogenicity of people vaccinated against COVID-19
(PM)Session 2 (Virtual) : How to use and integrate whole genome sequencing into One Health AMR surveillance programmes
(PM)Session 3 : Development of the novel Tuberculosis vaccine applied to various platforms in Korea
(PM)Session 4 (Virtual) : Overview of TB vaccine development
Question 2
Choose the topic
Session 1 (Virtual) : Building a novel pandemic preparedness program
Session 2 : Development of therapeutic human monoclonal antibodies against SFTSV infection
Session 3 : Bacteriophages and Endolysins Combating Multidrug Resistant (MDR) Pathogens
Session 4 : NIH-Supported Clinical Trial of Phage Therapy for Cystic Fibrosis Begins
Session 5 : Research status of TLR5’s immune adjuvant
Session 6 : accine adjuvants research
Session 7 : The future of pandemic preparedness: Building collaborations and EV-D68 as a test case for NIAID/VRC's PREMISE program
(AM)Session 1 (Virtual) : One Health approach to antimicrobial resistance
(AM)Session 2 (Virtual) : One Health Antimicrobial Resistance research landscape in Singapore
(AM)Session 3 (Virtual) : Population CPE evolution in Singapore
(AM)Session 4 (Virtual) : Long Covid-19
(AM)Session 5 (Virtual) : Long COVID treatment trials: pathogenesis guides intervention
(PM)Session 1 (Virtual) : A research about national seroepidemiology and immunogenicity of people vaccinated against COVID-19
(PM)Session 2 (Virtual) : How to use and integrate whole genome sequencing into One Health AMR surveillance programmes
(PM)Session 3 : Development of the novel Tuberculosis vaccine applied to various platforms in Korea
(PM)Session 4 (Virtual) : Overview of TB vaccine development
Question 3
Choose the topic
Session 1 (Virtual) : Building a novel pandemic preparedness program
Session 2 : Development of therapeutic human monoclonal antibodies against SFTSV infection
Session 3 : Bacteriophages and Endolysins Combating Multidrug Resistant (MDR) Pathogens
Session 4 : NIH-Supported Clinical Trial of Phage Therapy for Cystic Fibrosis Begins
Session 5 : Research status of TLR5’s immune adjuvant
Session 6 : accine adjuvants research
Session 7 : The future of pandemic preparedness: Building collaborations and EV-D68 as a test case for NIAID/VRC's PREMISE program
(AM)Session 1 (Virtual) : One Health approach to antimicrobial resistance
(AM)Session 2 (Virtual) : One Health Antimicrobial Resistance research landscape in Singapore
(AM)Session 3 (Virtual) : Population CPE evolution in Singapore
(AM)Session 4 (Virtual) : Long Covid-19
(AM)Session 5 (Virtual) : Long COVID treatment trials: pathogenesis guides intervention
(PM)Session 1 (Virtual) : A research about national seroepidemiology and immunogenicity of people vaccinated against COVID-19
(PM)Session 2 (Virtual) : How to use and integrate whole genome sequencing into One Health AMR surveillance programmes
(PM)Session 3 : Development of the novel Tuberculosis vaccine applied to various platforms in Korea
(PM)Session 4 (Virtual) : Overview of TB vaccine development
Personal and condition agreement
“1st International Symposium for Infectious Diseases Research Institutes Cooperation” is prohibited from distributing disagreed information for any other public related reasons nor as providing to third party without official agreement
Collected personal information is not used for other purposes besides the symposium.
Registration
